Immediate Impact
1 by Nobel laureates 1 from Science/Nature 49 standout
Citing Papers
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Targeting ROS in cancer: rationale and strategies
2024 Standout
Works of Georges Azzi being referenced
Phase III trial of sitravatinib plus nivolumab vs. docetaxel for treatment of NSCLC after platinum-based chemotherapy and immunotherapy (SAPPHIRE).
2020
Isocitrate dehydrogenase mutations in chondrosarcoma
2014
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Georges Azzi | 228 | 68 | 32 | 155 | 89 | 14 | 390 | |
| Leanne McCulloch | 199 | 16 | 18 | 66 | 71 | 16 | 446 | |
| Edina Tolnay | 114 | 40 | 22 | 64 | 237 | 16 | 385 | |
| Min Tang | 307 | 70 | 18 | 31 | 91 | 18 | 455 | |
| Johannes A. M. te Poele | 61 | 52 | 17 | 158 | 101 | 17 | 452 | |
| Simone M. Mrotzek | 168 | 18 | 39 | 214 | 61 | 15 | 395 | |
| John C. Champion | 115 | 16 | 27 | 220 | 74 | 9 | 349 | |
| Mariam Jafri | 61 | 122 | 30 | 70 | 98 | 14 | 343 | |
| Pierre‐Marie Morice | 228 | 44 | 16 | 75 | 37 | 20 | 359 | |
| George Orphanos | 219 | 33 | 37 | 104 | 97 | 18 | 427 | |
| Rupal O’Quinn | 196 | 16 | 33 | 227 | 42 | 20 | 406 |
All Works
Loading papers...